DE69611247D1 - Übersättigte transdermale arzneistoffabgabesysteme und verfahren zu deren herstellung - Google Patents

Übersättigte transdermale arzneistoffabgabesysteme und verfahren zu deren herstellung

Info

Publication number
DE69611247D1
DE69611247D1 DE69611247T DE69611247T DE69611247D1 DE 69611247 D1 DE69611247 D1 DE 69611247D1 DE 69611247 T DE69611247 T DE 69611247T DE 69611247 T DE69611247 T DE 69611247T DE 69611247 D1 DE69611247 D1 DE 69611247D1
Authority
DE
Germany
Prior art keywords
drug
delivery systems
drug delivery
supplied
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69611247T
Other languages
English (en)
Other versions
DE69611247T2 (de
Inventor
C Farinas
M Miller
L Soni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of DE69611247D1 publication Critical patent/DE69611247D1/de
Application granted granted Critical
Publication of DE69611247T2 publication Critical patent/DE69611247T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69611247T 1995-09-08 1996-09-06 Übersättigte transdermale arzneistoffabgabesysteme und verfahren zu deren herstellung Expired - Lifetime DE69611247T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52586795A 1995-09-08 1995-09-08
US08/708,389 US5906830A (en) 1995-09-08 1996-09-04 Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
PCT/US1996/014331 WO1997010812A2 (en) 1995-09-08 1996-09-06 Supersaturated transdermal drug delivery systems, and methods for manufacturing the same

Publications (2)

Publication Number Publication Date
DE69611247D1 true DE69611247D1 (de) 2001-01-18
DE69611247T2 DE69611247T2 (de) 2001-09-06

Family

ID=27061927

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69611247T Expired - Lifetime DE69611247T2 (de) 1995-09-08 1996-09-06 Übersättigte transdermale arzneistoffabgabesysteme und verfahren zu deren herstellung

Country Status (12)

Country Link
US (1) US5906830A (de)
EP (1) EP0848608B1 (de)
JP (1) JP3566301B2 (de)
AT (1) ATE198042T1 (de)
AU (1) AU6968296A (de)
CA (1) CA2229184C (de)
DE (1) DE69611247T2 (de)
DK (1) DK0848608T3 (de)
ES (1) ES2154832T3 (de)
GR (1) GR3035441T3 (de)
PT (1) PT848608E (de)
WO (1) WO1997010812A2 (de)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284266B1 (en) 1995-07-28 2001-09-04 Zars, Inc. Methods and apparatus for improved administration of fentanyl and sufentanil
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
ATE226816T1 (de) * 1996-07-03 2002-11-15 Alza Corp Vorrichtungen zur arzneistoffabgabe und herstellungsverfahren
IL123813A0 (en) * 1997-04-11 1998-10-30 Akzo Nobel Nv Drug delivery system for two or more active substances
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
GB9720470D0 (en) * 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
US7066884B2 (en) * 1998-01-08 2006-06-27 Sontra Medical, Inc. System, method, and device for non-invasive body fluid sampling and analysis
US20060015058A1 (en) * 1998-01-08 2006-01-19 Kellogg Scott C Agents and methods for enhancement of transdermal transport
US8287483B2 (en) 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
SE9801704D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
SE9801705D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
US6726673B1 (en) 1999-05-24 2004-04-27 Zars, Inc. Methods and apparatus for improved administration of testosterone pharmaceuticals
US6955819B2 (en) 1998-09-29 2005-10-18 Zars, Inc. Methods and apparatus for using controlled heat to regulate transdermal and controlled release delivery of fentanyl, other analgesics, and other medical substances
US20040171980A1 (en) 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
KR100858856B1 (ko) † 1999-02-08 2008-09-17 인타르시아 세라퓨틱스 인코포레이티드 안정한 비수성 단일상 점성 비히클 및 그 비히클을이용하는 제형물
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
FR2793689B1 (fr) * 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
WO2000074661A2 (en) 1999-06-05 2000-12-14 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
CA2374930C (en) 1999-07-02 2008-08-05 Lts Lohmann Therapie-Systeme Ag Microreservoir system based on polysiloxanes and ambiphilic solvents
US6453648B1 (en) 1999-07-06 2002-09-24 Zars, Inc. Method for manufacturing a heat generating apparatus
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
DE10012908B4 (de) * 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
DE10103860B4 (de) * 2001-01-30 2004-12-23 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System für die Verabreichung carboxylgruppenhaltiger, nichtsteroidaler Antiphlogistika, sowie Verfahren zu seiner Herstellung
US20050209208A1 (en) * 2001-04-25 2005-09-22 The Regents Of The University Of California Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
DE10212864B4 (de) * 2002-03-22 2005-12-22 Beiersdorf Ag Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
IL166687A0 (en) * 2002-08-30 2006-01-15 Alza Corp Embossable and writable multilaminate backing construction
US20040086551A1 (en) * 2002-10-30 2004-05-06 Miller Kenneth J. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
EP1426049B1 (de) * 2002-12-02 2005-05-18 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
CA2515918C (en) * 2003-02-21 2010-11-16 Schering Ag Uv stable transdermal therapeutic plaster
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
US8784874B2 (en) * 2003-09-10 2014-07-22 Noven Pharmaceuticals, Inc. Multi-layer transdermal drug delivery device
GB0322342D0 (en) * 2003-09-23 2003-10-22 Gamble Reed Skin patch
ME00114B (me) * 2003-10-28 2011-02-10 Noven Pharma Kompozicije i postupci za kontrolisanje gubitka i oslobađanja lijeka u transdermalnim sistemima oslobađanja lijeka
IL159273A0 (en) * 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
KR20070053267A (ko) * 2004-08-20 2007-05-23 쓰리엠 이노베이티브 프로퍼티즈 컴파니 반투명 보호 필름을 갖는 경피 약물 전달 장치
WO2006041907A2 (en) * 2004-10-08 2006-04-20 Noven Pharmaceuticals, Inc. Transdermal delivery of estradiol
US8252319B2 (en) * 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US8246977B2 (en) * 2004-10-21 2012-08-21 Durect Corporation Transdermal delivery systems
US20060094944A1 (en) * 2004-10-28 2006-05-04 Sontra Medical Corporation System and method for analyte sampling and analysis with error correction
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20060188558A1 (en) * 2005-02-18 2006-08-24 Mylan Technologies, Inc. Transdermal systems having control delivery system
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
WO2006135785A2 (en) * 2005-06-10 2006-12-21 Medical College Of Georgia Research Institute Compositions and methods for treating immune disorders
JP2008543359A (ja) * 2005-06-10 2008-12-04 トランスファーマ メディカル，リミティド 経皮投薬用のパッチ
TWI419717B (zh) * 2005-06-17 2013-12-21 Altea Therapeutics Corp 滲透傳送系統及其使用方法
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
GEP20125432B (en) 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
US7432069B2 (en) * 2005-12-05 2008-10-07 Sontra Medical Corporation Biocompatible chemically crosslinked hydrogels for glucose sensing
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
CA2653782A1 (en) 2006-06-14 2007-12-21 Dr. Reddy's Laboratories Limited Topical compositions
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
DK2117521T3 (da) 2006-11-03 2012-09-03 Durect Corp Transdermale indgivelsessystemer omfattende bupivacain
NZ580179A (en) * 2007-03-07 2011-06-30 Echo Therapeutics Inc Transdermal analyte monitoring systems and methods for analyte detection
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
DE602008005299D1 (de) 2007-04-27 2011-04-14 Echo Therapeutics Inc Hautpermeationsvorrichtung für Analytenmessung oder transdermale Arzneiabgabe
US20100293807A1 (en) * 2007-10-29 2010-11-25 Transpharma Medical, Ltd. Vertical patch drying
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
CN102083418A (zh) * 2008-04-24 2011-06-01 伊万斯彻有限公司 口服避孕药剂及其制备方法
US20090291127A1 (en) * 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
WO2009158120A2 (en) * 2008-05-30 2009-12-30 Mylan Laboratories Inc. Stabilized transdermal drug delivery system
US8231906B2 (en) * 2008-07-10 2012-07-31 Noven Pharmaceuticals, Inc. Transdermal estrogen device and delivery
WO2010039381A1 (en) * 2008-09-30 2010-04-08 Teikoku Pharma Usa, Inc. Transdermal extended-delivery donepezil compositions and methods for using the same
EP2742934A1 (de) 2008-10-06 2014-06-18 Mylan Technologies, Inc. Amorphes transdermales Rotigotin-System
CA2757302A1 (en) * 2009-04-01 2010-10-07 Andrew Crockett Methods for treating myofascial, muscle, and/or back pain
US9186334B2 (en) 2009-05-04 2015-11-17 Nuvo Research Inc. Heat assisted lidocaine and tetracaine for transdermal analgesia
US9186273B2 (en) * 2009-05-04 2015-11-17 Nuvo Research Inc. Methods of treating pains associated with neuroma, nerve entrapment, and other conditions
EP2459184A1 (de) 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation der sgk1-expression bei th17-zellen zur modulation von th17-vermittelten immunreaktionen
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
AU2011238710B2 (en) * 2010-03-28 2015-08-20 Evestra, Inc. Intravaginal drug delivery device
JP5766475B2 (ja) 2010-03-30 2015-08-19 日東電工株式会社 貼付製剤およびその製造方法
CA2794565C (en) 2010-04-08 2018-08-21 Emory University Substituted androst-4-ene diones
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2830069C (en) 2011-03-20 2019-11-12 The University Of British Columbia Therapeutic agent for emphysema and copd
WO2012151474A2 (en) 2011-05-04 2012-11-08 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
JPWO2012165254A1 (ja) 2011-05-31 2015-02-23 久光製薬株式会社 ロピニロール含有貼付剤及びその包装体
EP2716286B1 (de) 2011-05-31 2017-07-12 Hisamitsu Pharmaceutical Co., Inc. Ropinirolhaltiges klebepflaster und verpackung dafür
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2543370A1 (de) 2011-07-06 2013-01-09 Georgia Health Sciences University Research Institute, Inc. Zusammensetzungen und Verfahren zur Behandlung des Herpes-simplex-Virus
CA2790749A1 (en) 2011-09-29 2013-03-29 Nitto Denko Corporation Manufacturing method of patch preparation
WO2013071049A1 (en) 2011-11-10 2013-05-16 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
JP5270035B1 (ja) * 2012-12-06 2013-08-21 久光製薬株式会社 貼付剤及びその製造方法
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP5307931B1 (ja) 2012-12-27 2013-10-02 久光製薬株式会社 貼付剤及びその製造方法
CN103919755B (zh) * 2013-01-15 2019-10-18 江苏康倍得药业股份有限公司 妥洛特罗透皮贴剂及其制备方法
CN103933018A (zh) * 2013-01-18 2014-07-23 江苏康倍得药业有限公司 一种透皮给药系统
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
JP5415645B1 (ja) 2013-06-28 2014-02-12 久光製薬株式会社 貼付剤の製造方法、貼付剤及び包装体
EP3036226B1 (de) 2013-08-22 2020-01-08 The General Hospital Corporation Hemmer der humanen 12/15-lipoxygenase
WO2015031765A2 (en) 2013-08-29 2015-03-05 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10493027B2 (en) * 2014-08-07 2019-12-03 Mucodel Pharma Llc Chemically stable compositions of a pharmaceutical active agent in a multi- chambered delivery system for mucosal delivery
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
EP3303286B1 (de) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center An rela von nf-kb anbindende verbindungen zur verwendung bei der behandlung von krebs
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017017631A2 (en) 2015-07-28 2017-02-02 Vyome Biosciences Pvt. Ltd. Antibacterial therapeutics and prophylactics
WO2017059070A1 (en) 2015-09-29 2017-04-06 Amag Pharmaceuticals, Inc. Crystalline and amorphous form of 17-a- hydroxyprogesterone caproate
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE217989C (de) *
DE2920500A1 (de) * 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim Pharmazeutische zubereitung in form eines polyacrylatfilmes
FR2542998B1 (fr) * 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
AU560710B2 (en) * 1983-04-27 1987-04-16 Lohmann Gmbh & Co. Kg. Pharmaceutical product
US4883669A (en) * 1985-02-25 1989-11-28 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration
JPH066534B2 (ja) * 1986-10-09 1994-01-26 積水化学工業株式会社 経皮吸収貼付剤
US4832953A (en) * 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE3910543A1 (de) * 1989-04-01 1990-10-11 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
EP0523150A4 (en) * 1990-04-06 1993-09-29 Pharmetrix Corporation Device and method for enhanced administration of physostigmine
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
CA2060113A1 (en) * 1991-02-01 1992-08-02 Agis Kydonieus Temperature activated controlled release device
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
DE4237453C1 (de) * 1992-11-06 1993-08-19 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
WO1997009971A2 (en) * 1995-09-14 1997-03-20 Cygnus, Inc. High capacity, superabsorbent drug reservoirs for use in transdermal drug delivery systems
WO1997024148A1 (en) * 1995-12-29 1997-07-10 Cygnus, Inc. Systems and methods for the transdermal administration of androgenic agents

Also Published As

Publication number Publication date
JP3566301B2 (ja) 2004-09-15
ES2154832T3 (es) 2001-04-16
CA2229184C (en) 2001-07-24
DK0848608T3 (da) 2001-02-19
PT848608E (pt) 2001-03-30
US5906830A (en) 1999-05-25
GR3035441T3 (en) 2001-05-31
CA2229184A1 (en) 1997-03-27
DE69611247T2 (de) 2001-09-06
EP0848608B1 (de) 2000-12-13
WO1997010812A2 (en) 1997-03-27
ATE198042T1 (de) 2000-12-15
AU6968296A (en) 1997-04-09
EP0848608A2 (de) 1998-06-24
JP2002504070A (ja) 2002-02-05

Similar Documents

Publication Publication Date Title
DE69611247D1 (de) Übersättigte transdermale arzneistoffabgabesysteme und verfahren zu deren herstellung
DE3581268D1 (de) Vorrichtung mit aminbestaendigem silikonklebstoff fuer die transdermale medikamentenzufuhr und verfahren zu dessen herstellung.
DE68923805D1 (de) Verfahren zur herstellung von optisch aktivem 1,3-butanediol.
DE69330181T2 (de) Mehrschichtiger vliesstoff, verfahren und vorrichtung zu dessen herstellung, sowie diesen vliesstoff enthaltende absorbierende produkte
DE69525444T2 (de) Verfahren zur herstellung von biologisch aktiven siliziumverbindungen in konzentrierter form
DE3673073D1 (de) Therapeutische brausemischung sowie verfahren zu deren herstellung.
DE3768530D1 (de) Methacrylatharz-zusammensetzung und verfahren zu deren herstellung.
DK0384266T3 (da) Terapeutisk system til forsinket og styret transdermal eller transmucosal afgivelse af virksomme stoffer
DE3860769D1 (de) Polymer-zusammensetzung, verfahren zu deren herstellung und deren anwendung.
DE3669328D1 (de) Verfahren und anlage zur serienmaessigen, verzugsarmen thermomechanischen behandlung von werkstuecken sowie anwendung des verfahrens.
DK144694A (da) Fremgangsmåde til fremstilling af en optisk ren enantiomer af formoterol
ATE153999T1 (de) Herstellung von optisch aktiven hydrazinen und aminen
DE58901324D1 (de) Verfahren zur herstellung von solarsilicium.
DE68914638D1 (de) Polyaluminosilikat-mikrogel, verfahren und zusammensetzung.
DE3766708D1 (de) Silylgruppen enthaltendes verzweigtes polymerisat, verfahren zu seiner herstellung, ueberzugsmittel auf basis des polymerisats sowie deren verwendung.
DE3579673D1 (de) Polyazaheterozyklische abkoemmlinge, verfahren zu deren herstellung sowie arzneimittelzusammensetzung.
DK188680A (da) Fremgangsmaade til fremstilling af 6-substituerede 11-alkylenmorphantridiner
DE3685210D1 (de) 1-benzensulfonyl-2-oxo-5-alkoxypyrrolidine, verfahren zu deren herstellung und deren anwendung als heilmittel sowie diese enthaltende zusammenstellungen.
DK1006200T3 (da) Fremgangsmåde til fremstilling af udvalgte interstreng-tværbindinger i nukleinsyrer og anvendelser deraf
DK0546389T3 (da) Piperidylmethylsubstituerede chromanderivater som virksomme stoffer til behandling af sygdomme i centralnervesystemet
DE3883366D1 (de) Fluessigkristall-verbindung und verfahren zu deren herstellung, dieselbe enthaltende fluessigkristallzusammensetzung und fluessigkristall-anzeigevorrichtung.
EP0702960A4 (de) Flüssige globulinzubereitung für die intravenöse injektion, verfahren für ihre herstellung, und methode zur blockierung der globulindimerisierung in besagter zubereitung
NO870869D0 (no) Innretning for forstyrrelse av navigasjonsanlegg basert paa forplanting av lydboelger i vann.
DE69418661T2 (de) Blockcopolymerzusammensetzung, diese enthaltende Heissschmelzkleberzusammensetzung und Verfahren zu deren Herstellung
PT909167E (pt) Dispositivos de fornecimento de drogas e processo de fabrico

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN